Malarone

Atovaquone/Proguanil, the active ingredient in Malarone, is an antimalarial presented as a 250 mg Atovaquone / 100 mg Proguanil tablet for oral use. It is indicated for the prevention of malaria and for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum and Plasmodium vivax in travelers, military personnel and residents of endemic regions.

GNH USA supplies Malarone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with a focus on quality assurance and regulatory compliance.

Malarone (atovaquone/proguanil) is used in the antimalarial therapeutic class for both prophylaxis and treatment of malaria. - Prevention of malaria: provides chemoprophylaxis for travelers and residents in areas with Plasmodium falciparum and Plasmodium vivax transmission. - Treatment of acute uncomplicated malaria: clears susceptible Plasmodium falciparum infections when administered as directed. - Treatment of acute uncomplicated malaria caused by Plasmodium vivax: effective against susceptible strains of P. vivax.

Malarone may cause a range of adverse reactions, which are generally classified as common or serious.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Abdominal pain: discomfort or cramps. - Diarrhea: loose stools. - Headache: mild to moderate. - Dizziness: transient vertigo or light‑headedness. - Metallic taste: altered taste perception.

Serious or Rare Side Effects: - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity: elevated liver enzymes or hepatitis. - Hemolytic anemia: especially in patients with G6PD deficiency. - Severe hypersensitivity: anaphylaxis or angioedema.

Before using Malarone, consider the following precautions. - Medical history: assess for G6PD deficiency, liver disease, or renal impairment before initiating therapy. - Pregnancy and lactation: use only if potential benefit outweighs risk, as safety data are limited. - Concomitant medications: review for drugs that may affect atovaquone absorption (e.g., antacids, rifampin). - Food intake: take with a fatty meal to improve atovaquone absorption. - Adherence: complete the full course as prescribed to prevent treatment failure and resistance. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Malarone can interact with several medicines; interactions are grouped by clinical significance.

Major Interactions (Avoid): - Rifampin: induces hepatic enzymes, markedly reduces atovaquone levels. - Antacids containing aluminum or magnesium: decrease atovaquone absorption. - Certain antiretrovirals (e.g., efavirenz): may lower atovaquone concentrations. - Warfarin: potential alteration of anticoagulant effect; monitor INR closely. - Highly active antiretroviral therapy (HAART) regimens: may reduce efficacy.

Moderate Interactions (Monitor Closely): - Cimetidine: may increase atovaquone exposure. - Ketoconazole: may increase atovaquone levels. - Digoxin: monitor for possible increased serum concentrations. - Statins (e.g., simvastatin): monitor for enhanced risk of myopathy. - Oral contraceptives: advise additional contraceptive measures.